Craneware plc

Craneware plc

CRW.L
Craneware plcGB flagLondon Stock Exchange
1,110.00
GBp
-8.00
- -
380.03MMarket Cap
Craneware plc
CRW.L
(London Stock Exchange)

Recent

price

1,110.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
1.12
1.46
1.52
1.54
1.58
1.67
1.86
2.15
2.5
2.68
2.67
2.82
4.72
4.95
5.41
- -
Revenue per Share
0.22
0.23
0.33
0.31
0.32
0.35
0.39
0.5
0.59
0.56
0.63
0.48
0.27
0.26
0.33
- -
Basic EPS, GAAP
0.24
0.25
0.32
0.23
0.28
0.69
0.48
0.49
0.94
0.11
0.4
0.87
0.76
2.79
1.16
- -
Free Cash Flow per Basic Share
0.12
0.12
0.15
0.17
0.2
0.2
0.22
0.24
0.29
0.32
0.34
0.36
0.37
0.34
0.37
- -
Dividend per Share
0.38
0.65
0.81
0.95
1.08
1.11
1.3
1.5
1.11
1.36
1.61
1.77
1.22
1.15
1.14
- -
Book Value per Share
0.81
0.6
0.8
0.96
1.13
1.17
1.35
1.47
1.06
1.1
1.18
8.1
-3.79
-3.53
-3.11
- -
Tangible Book Value per Share
25
26
27
27
27
27
27
27
27
27
27
27
35
35
35
35
Basic Weighted Avg Shares
28
38
41
41
43
45
50
58
67
71
71
76
166
174
189
- -
Sales/Revenue/Turnover
24.81
23.9
24.64
25.58
26.47
28.05
28.91
28.55
27.72
26.95
26.88
26.16
11.23
9.86
11.01
- -
Operating Margin (%)
- -
1
2
2
2
1
2
1
2
4
5
5
29
32
33
- -
Depreciation Expense
6
6
9
8
9
9
11
14
16
15
17
13
9
9
12
- -
Net Income, GAAP
23.87
30.49
20.61
21.76
23.74
24.87
24.05
19.89
16.56
18.21
12.78
1.97
28.19
29.45
25.68
- -
Effective Tax Rate (%)
19.46
15.78
21.65
20.01
20.22
20.95
21.22
23.4
23.55
20.99
23.55
17.08
5.68
5.31
6.18
- -
Profit Margin (%)
19
14
18
23
28
27
29
31
18
20
24
206
10
-13
-56
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
105
77
31
- -
LT Debt
22
32
37
41
45
48
53
59
52
60
68
260
333
328
329
- -
Total Equity
25.61
23.35
22.8
20.63
19.72
20.19
21.43
23.55
28.5
28.53
25.77
11.67
3.79
2.83
3.95
- -
Return on Invested Capital (%)
69.65
45.52
45.98
34.98
31.42
31.78
32.69
35.96
45.01
45.39
41.08
27.11
12.52
9.6
14.96
- -
Return on Capital (%)
69.65
45.52
45.98
34.98
31.42
31.78
32.69
35.96
45.01
45.39
42.41
28.49
20.83
22.13
29.06
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
189
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.33
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.37
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Craneware plc (LSE: CRW) develops and provides mission-critical SaaS solutions for the healthcare sector, with a primary focus on revenue integrity, patient engagement, and financial performance management for hospitals and health systems. The company offers a comprehensive suite of products including Trisus Revenue Cycle, its flagship platform for end-to-end revenue cycle management; ChargeTRUE for automated charge capture and compliance; Trisus Decision Analytics for data-driven insights; Patient Engagement Portal for streamlined billing and payments; and Value Analytics for optimizing reimbursement strategies; as well as services encompassing implementation, training, managed services, and ongoing support. Craneware primarily serves acute care hospitals, integrated delivery networks, and children's hospitals in the United States, its core market, with expanding operations in the United Kingdom and select international regions. Founded in 1996 and headquartered in Edinburgh, Scotland, the company operates as a standalone entity listed on the London Stock Exchange's AIM market. In recent developments, Craneware completed the acquisition of Clinion in late 2023, enhancing its pharmacy revenue integrity capabilities and marking a strategic expansion into specialized clinical workflows. The company reported robust growth in fiscal 2025, driven by strong recurring SaaS revenue and new client wins, including major U.S. health systems adopting its Trisus platform amid rising demand for revenue optimization tools. Additionally, Craneware announced partnerships with leading electronic health record (EHR) providers to integrate its solutions more seamlessly, supporting broader adoption in value-based care environments.